Carol Grieder

Dear Research Advocate, Congress has passed a spending bill for what remains of the current fiscal year, which ends September 30. Preliminary agency funding levels have been reported by Nature . The appropriations process remains important for making up some small amount of the ground lost to sequestration, but as long as sequestration remains the law of the land, annual cuts to NIH, FDA and our nation’€™s other health research agencies are all but assured ; and with it, the insidious ripple effect of damage to grantees, vendors, and the pharma, bio and device industries that partner with researchers to develop the products patients await. That’€™s the bottom line. We must remind our...
Dear Research Advocate, To say that the attention paid to sequestration is extraordinary is to understate the case, but there has not been enough public outcry to force meaningful congressional action. It is highly unlikely that a rabbit will be pulled out of a hat between now and 11:59 p.m. tomorrow night. Damage will be done, and meanwhile the political playing field switches to a new month and new, related and ever-deepening crises. Possibly the only good news is that the media has ratcheted up coverage of the impact of sequestration on medical research, with stories about ’€œcuts on top of cuts on top of cuts,’€ in the words of Eric Hoffman of Children’€™s National Medical Center, one...

Sidebar Quote

The capabilities are enormous, a little bit of research can pay off quite a bit in the long run.
Paul D’ Addario, retinitis pigmentosa patient